Continued treatment with secukinumab is associated with high retention or regain of response.

Augustin, M

Continued treatment with secukinumab is associated with high retention or regain of response. [electronic resource] - The British journal of dermatology 01 2020 - 67-75 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1365-2133

10.1111/bjd.17991 doi


Antibodies, Monoclonal, Humanized
Etanercept
Humans
Psoriasis--drug therapy
Randomized Controlled Trials as Topic
Severity of Illness Index
Treatment Outcome
Ustekinumab